Tuberculosis Case Finding With Combined Rapid Point-of-Care Assays (Xpert MTB/RIF and Determine TB LAM) in HIV-Positive Individuals Starting Antiretroviral Therapy in Mozambique

摘要

Tuberculosis prevalence among 972 human immunodeficiency virus–positive Mozambican patients starting antiretroviral therapy was 10%, with limited rifampicin resistance. A repeated Xpert MTB/RIF sputum test, combined with the rapid urinary Determine TB LAM test, improved case finding, with a short interval to tuberculosis treatment.